Intrexon Corporation, founded in 1998, is a biotechnology company focused on collaborating with companies in Health, Food, Energy, and Environment to create biologically based products that improve quality of life and the health of the planet. At present rates of global industrialization and population growth, food and energy supplies and environmental and healthcare resources are becoming scarcer. We believe Intrexon’s leading Better DNA™ approach to synthetic biology has the potential to provide new, more effective and sustainable solutions to address these challenges.
With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells. Working with key collaborators, Intrexon seeks to develop high value applications that can bring better medicines to more people, alleviate shortages of essential nutrients, develop renewable fuels and other resources, and protect the environment.
Intrexon’s principal corporate office is located at:
20374 Seneca Meadows Parkway
Germantown, Maryland 20876
Telephone: (301) 556-9900
The Company was founded by Thomas D. Reed, Ph.D., in 1998, as an Ohio limited liability company under the name Genomatix LTD. The Company was reincorporated as a Virginia corporation in 2004 and changed its name to Intrexon Corporation in 2005.
Shares of Intrexon trade on the New York Stock Exchange under the symbol XON.
No, Intrexon does not offer a direct investment program. Interested investors may purchase shares through any registered broker.
J.P. Morgan Securities LLC and Barclays Capital Inc. served as joint book-running managers for the offering.
The Company closed its initial public offering of on August 13, 2013. The Company announced the total number of shares sold was 11,499,998, composed of 9,999,999 shares initially offered and an additional 1,499,999 shares sold pursuant to the full exercise of the underwriters’ over-allotment option, in each case at an initial public offering price of $16.00 per share. All of the common stock was sold by Intrexon.
Intrexon’s fiscal year end is December 31.
Intrexon reports earnings results on a quarterly basis. For our upcoming earnings announcements and other investor events, please see our Calendar of Events.
The Company’s independent auditor is PricewaterhouseCoopers LLC.
The Company’s transfer agent is:
American Stock Transfer & Trust Company, LLC.,
6201 15th Avenue, Brooklyn, NY 11219
For questions concerning stock holdings, certificate replacement/transfer, and address changes, please contact our transfer agent:
American Stock Transfer & Trust Company, LLC
Shareholder Relations Services Department
6201 15th Avenue, Brooklyn, NY 11219
Annual 10-K reports, quarterly 10-Q reports, proxy statements and other filings with the SEC can be accessed directly through the SEC Filings section of Intrexon’s website or through the Securities and Exchange Commission at www.sec.gov. If you would like a hard copy of the annual report, please submit your request through our Information Request form.
Shareholders can access general educational information on shareholder rights and the proxy voting process on third party sites. Below are several links that may be helpful to shareholders:
- U.S. Securities and Exchange Commission--Spotlight on Proxy Matters: http://sec.gov/spotlight/proxymatters.shtml
- U.S. Securities and Exchange Commission--Investor Alert on New Shareholder Voting Rules for the 2010 Proxy Season:http://sec.gov/investor/alerts/votingrules2010.htm
Interested parties may contact these persons as directed in Appendix B to our Corporate Governance Guidelines.
For information on career opportunities at Intrexon, please visit the Careers section of the Company’s website.
Go to the Information Request page.